2022 | 2023 | 2025 | 2027 | ||
Indication | Discovery | Preclinical | Phase1 | Phase2 | Phase3 |
Pancreatic cancer inhibitor 1 (CY101) | |||||
Pancreatic cancer inhibitor 2 (GJ101) | |||||
Lung cancer inhibitor (GJ501) | |||||
Colorectal cancer inhibitor (GJ105) | |||||
Cancer of the liver inhibitor (GJ108) | |||||
A cure for dementia (GJ106) | |||||
Anti-inflammatory drugs (GJ107) | |||||
Virus inhibitors | |||||
Diagnosis kits |
+82-51-581-2544
Mon - Fri AM 09:00 - 18:00
Lunch pm 12:00 - pm 01:00
Sat.Sun.Red-Day Off
Head office : 407B, Hyowon University-Industry Cooperation Bldg., 2 Busandaehak-ro 63beon-gil, Geumjeong-gu, Busan, 46241, Republic of KOREA
EMAIL : infogjmedi@naver.com
Business name : GJMEDI INC. CEO : Se Bok Jang and Mi Suk Jeong
Business registration number : 173-88-01396
Online sales registration : No. 2020-Busan Geumjeong-0259
Personal information manager: Mi Suk Jeong
Tel: +82-51-581-2544 / Fax: +82-51-581-2545 /infogjmedi@naver.com